BioCardia to Support Development of Potential Cell Therapy Products

The facility is being expanded to support the manufacturing of CardiAMP Cell Therapy Systems, allogeneic NK1R+ MSC, and biotherapeutic delivery devices for clinical trials and early commercial activities across many programs.

FREMONT, CA: Cell therapy is used to treat cancer, autoimmune disease, urinary difficulties, and infectious disease, as well as to heal damaged cartilage in joints, spinal cord injuries, strengthen a weakened immune system, and assist individuals with neurological abnormalities. BioCardia, Inc., a developer of cellular and cell-derived medicines to treat cardiovascular and pulmonary illnesses, has leased a new site in Sunnyvale, California, for an indefinite period. This facility is being expanded to accommodate BioCardia's cell and device products and product candidates in the Company's therapeutic pipeline.

"We have always believed that manufacturing during development needs to be kept close to capture new insights and innovate rapidly. Controlling manufacturing at this stage helps accelerate the development of our cell-based medicines, which we also believe is a key differentiator of BioCardia from many other cellular therapeutics companies," comments Peter Altman, BioCardias President and CEO.

 "We expect to soon see all four of the programs we discuss publicly in the clinic helping patients, with our in-house facilities providing the material."

The Company's patented biotherapeutic delivery systems, which the Company also selectively licenses to other biotherapeutic development organizations, are at the heart of three experimental medicines. NK1R+ allogenic bone marrow-derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases are being developed by BioCardia, Inc., based in San Carlos, California, as are CardiAMP cardiovascular-specific mononuclear cell therapy and CardiAMP allogenic cardiovascular-specific mesenchymal stem cell therapies. Products that could benefit millions of people can support these four platforms.

BioCardias' new production facility is planned to produce CardiAMP Cell Therapy Systems, NK1R+ stem cells, and Biotherapeutic Delivery Devices to support various clinical trials and early commercial activities.